INTRODUCTION: Herpes Simplex Virus-2 (HSV-2) is known to be a potent co-factor of Human Immunodeficiency type 1 virus (HIV-1) heterosexual transmission. We were interested in assessing the distribution of HIV-1 and HSV-2 epidemics at the national level in Chad. METHODOLOGY: In 2007, a population-based anonymous serosurvey for HIV-1 and HSV-2 infections, using dried blood spots, was conducted. The study included 548 adults living in 15 regions of Chad. After specimen elution, serological testing for HIV and HSV-2 infections was performed. RESULTS: Countrywide, the HIV-1 and HSV-2 seroprevalences were 11.1% and 15.7%, respectively. A positive correlation was observed with the highest HIV-1 prevalence seen in regions of the highest HSV-2 prevalence, especially in two conflict-affected eastern provinces of Darfur. CONCLUSION: Urgent public health interventions are needed in regions of Chad where high HSV-2 prevalence may be increasing the risk of HIV propagation.
INTRODUCTION:Herpes Simplex Virus-2 (HSV-2) is known to be a potent co-factor of HumanImmunodeficiency type 1 virus (HIV-1) heterosexual transmission. We were interested in assessing the distribution of HIV-1 and HSV-2 epidemics at the national level in Chad. METHODOLOGY: In 2007, a population-based anonymous serosurvey for HIV-1 and HSV-2 infections, using dried blood spots, was conducted. The study included 548 adults living in 15 regions of Chad. After specimen elution, serological testing for HIV and HSV-2 infections was performed. RESULTS: Countrywide, the HIV-1 and HSV-2 seroprevalences were 11.1% and 15.7%, respectively. A positive correlation was observed with the highest HIV-1 prevalence seen in regions of the highest HSV-2 prevalence, especially in two conflict-affected eastern provinces of Darfur. CONCLUSION: Urgent public health interventions are needed in regions of Chad where high HSV-2 prevalence may be increasing the risk of HIV propagation.
Authors: Philippe Van de Perre; Michel Segondy; Vincent Foulongne; Abdoulaye Ouedraogo; Issouf Konate; Jean-Marie Huraux; Philippe Mayaud; Nicolas Nagot Journal: Lancet Infect Dis Date: 2008-08 Impact factor: 25.071
Authors: F Behets; M Kashamuka; M Pappaioanou; T A Green; R W Ryder; V Batter; J R George; W H Hannon; T C Quinn Journal: J Clin Microbiol Date: 1992-05 Impact factor: 5.948
Authors: S S Solomon; S Pulimi; I I Rodriguez; S K Chaguturu; S K Satish Kumar; K H Mayer; S Solomon Journal: Int J STD AIDS Date: 2004-10 Impact factor: 1.359
Authors: C Toure Kane; S Diawara; H D Ndiaye; P A N Diallo; A S Wade; A G Diallo; L Belec; S Mboup Journal: Int J STD AIDS Date: 2009-11 Impact factor: 1.359
Authors: Deborah Watson-Jones; Helen A Weiss; Mary Rusizoka; John Changalucha; Kathy Baisley; Kokugonza Mugeye; Clare Tanton; David Ross; Dean Everett; Tim Clayton; Rebecca Balira; Louise Knight; Ian Hambleton; Jerome Le Goff; Laurent Belec; Richard Hayes Journal: N Engl J Med Date: 2008-03-12 Impact factor: 91.245
Authors: Laith J Abu-Raddad; Amalia S Magaret; Connie Celum; Anna Wald; Ira M Longini; Steven G Self; Lawrence Corey Journal: PLoS One Date: 2008-05-21 Impact factor: 3.240
Authors: Marcia M Hobbs; Sophie W Mwanyumba; Winnie K Luseno; Shane Hartman; Carolyn T Halpern; Denise D Hallfors; Hyunsan Cho Journal: Sex Transm Dis Date: 2017-02 Impact factor: 2.830
Authors: S Janssen; M A M Huson; S Bélard; S Stolp; N Kapata; M Bates; M van Vugt; M P Grobusch Journal: Infection Date: 2013-12-06 Impact factor: 3.553